| Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid … JC Byrd, K Mrózek, RK Dodge, AJ Carroll, CG Edwards, DC Arthur, ... Blood 100 (13), 4325-4336, 2002 | 2122 | 2002 |
| Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia KG Roberts, Y Li, D Payne-Turner, RC Harvey, YL Yang, D Pei, ... New England Journal of Medicine 371 (11), 1005-1015, 2014 | 1565 | 2014 |
| IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study G Marcucci, K Maharry, YZ Wu, MD Radmacher, K Mrózek, D Margeson, ... Journal of Clinical Oncology 28 (14), 2348-2355, 2010 | 997 | 2010 |
| Cytogenetics in acute leukemia K Mrózek, NA Heerema, CD Bloomfield Blood Reviews 18 (2), 115-136, 2004 | 986 | 2004 |
| Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B study P Paschka, G Marcucci, AS Ruppert, K Mrózek, H Chen, RA Kittles, ... Journal of Clinical Oncology 24 (24), 3904-3911, 2006 | 876 | 2006 |
| Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer … SP Whitman, KJ Archer, L Feng, C Baldus, B Becknell, BD Carlson, ... Cancer Research 61 (19), 7233-7239, 2001 | 828 | 2001 |
| Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular … K Mrózek, G Marcucci, P Paschka, SP Whitman, CD Bloomfield Blood 109 (2), 431-448, 2007 | 816 | 2007 |
| PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia Z Gu, ML Churchman, KG Roberts, I Moore, X Zhou, J Nakitandwe, ... Nature Genetics 51 (2), 296-307, 2019 | 552 | 2019 |
| MicroRNA expression in cytogenetically normal acute myeloid leukemia G Marcucci, MD Radmacher, K Maharry, K Mrózek, AS Ruppert, ... New England Journal of Medicine 358 (18), 1919-1928, 2008 | 544 | 2008 |
| Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia K Mrózek, G Marcucci, D Nicolet, KS Maharry, H Becker, SP Whitman, ... Journal of Clinical Oncology 30 (36), 4515-4523, 2012 | 539 | 2012 |
| High Frequency and Poor Outcome of Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia in Adults KG Roberts, Z Gu, D Payne-Turner, K McCastlain, RC Harvey, IM Chen, ... Journal of Clinical Oncology 35 (4), 394-401, 2017 | 476 | 2017 |
| Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study G Marcucci, K Mrózek, AS Ruppert, K Maharry, JE Kolitz, JO Moore, ... Journal of Clinical Oncology 23 (24), 5705-5717, 2005 | 459 | 2005 |
| Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene-and microRNA-expression … H Becker, G Marcucci, K Maharry, MD Radmacher, K Mrózek, ... Journal of Clinical Oncology 28 (4), 596-604, 2010 | 445 | 2010 |
| TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study KH Metzeler, K Maharry, MD Radmacher, K Mrózek, D Margeson, ... Journal of Clinical Oncology 29 (10), 1373-1381, 2011 | 444 | 2011 |
| A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403 W Stock, SM Luger, AS Advani, J Yin, RC Harvey, CG Mullighan, ... Blood 133 (14), 1548-1559, 2019 | 437 | 2019 |
| Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience M Wetzler, RK Dodge, K Mrózek, AJ Carroll, R Tantravahi, AMW Block, ... Blood 93 (11), 3983-3993, 1999 | 391 | 1999 |
| Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk … G Marcucci, K Maharry, MD Radmacher, K Mrózek, T Vukosavljevic, ... Journal of Clinical Oncology 26 (31), 5078-5087, 2008 | 377 | 2008 |
| Clinical significance of cytogenetics in acute myeloid leukemia. K Mrózek, K Heinonen, A de la Chapelle, CD Bloomfield Seminars in Oncology 24 (1), 17-31, 1997 | 366 | 1997 |
| FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal … SP Whitman, AS Ruppert, MD Radmacher, K Mrózek, P Paschka, ... Blood, The Journal of the American Society of Hematology 111 (3), 1552-1559, 2008 | 363 | 2008 |
| Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia … SS Farag, KJ Archer, K Mrózek, AS Ruppert, AJ Carroll, JW Vardiman, ... Blood 108 (1), 63-73, 2006 | 363 | 2006 |
Clara D. Bloomfield, MDThe Ohio State UniversityEmail verificata su osumc.edu